Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 932658, 7 pages
http://dx.doi.org/10.1155/2012/932658
Review Article

Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings

1Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
3Vaccine and Infectious Disease, Public Health Sciences, and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Received 1 December 2011; Accepted 23 January 2012

Academic Editor: Lisa K. Hicks

Copyright © 2012 Matthew Ulrickson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Diffuse, undifferentiated non-Hodgkins lymphoma among homosexual males—United States,” MMWR: Morbidity and Mortality Weekly Report, vol. 31, no. 21, pp. 277–279, 1982.
  2. J. L. Ziegler, W. L. Drew, and R. C. Miner, “Outbreak of Burkitt's-like lymphoma in homosexual men,” The Lancet, vol. 2, no. 8299, pp. 631–633, 1982. View at Google Scholar · View at Scopus
  3. V. Beral and R. Newton, “Overview of the epidemiology of immunodeficiency-associated cancers,” Journal of the National Cancer Institute, no. 23, pp. 1–6, 1998. View at Google Scholar · View at Scopus
  4. C. Casper, “The increasing burden of HIV-associated malignancies in resource-limited regions,” Annual Review of Medicine, vol. 62, pp. 157–170, 2011. View at Publisher · View at Google Scholar
  5. B. Ledergerber, A. Telenti, and M. Egger, “Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study,” British Medical Journal, vol. 318, no. 7201, pp. 23–24, 1999. View at Google Scholar · View at Scopus
  6. C. Besson, A. Goubar, J. Gabarre et al., “Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy,” Blood, vol. 98, no. 8, pp. 2339–2344, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Eltom, A. Jemal, S. M. Mbulaiteye, S. S. Devesa, and R. J. Biggar, “Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998,” Journal of the National Cancer Institute, vol. 94, no. 16, pp. 1204–1210, 2002. View at Google Scholar · View at Scopus
  8. M. S. Shiels, R. M. Pfeiffer, M. H. Gail et al., “Cancer burden in the HIV-infected population in the United States,” Journal of the National Cancer Institute, vol. 103, no. 9, pp. 753–762, 2011. View at Publisher · View at Google Scholar
  9. N. Clumeck, J. Sonnet, and H. Taelman, “Acquired immunodeficiency syndrome in African patients,” The New England Journal of Medicine, vol. 310, no. 8, pp. 492–497, 1984. View at Google Scholar · View at Scopus
  10. P. Van de Perre, P. Lepage, and D. Rouvroy, “Acquired immunodeficiency syndrome in Rwanda,” The Lancet, vol. 2, no. 8394, pp. 62–65, 1984. View at Google Scholar · View at Scopus
  11. D. M. Parkin, H. Wabinga, S. Nambooze, and F. Wabwire-Mangen, “AIDS-related cancers in Africa: maturation of the epidemic in Uganda,” AIDS, vol. 13, no. 18, pp. 2563–2570, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. K. A. Adeniji and A. S. Anjorin, “Peripheral lymphadenopathy in Nigeria,” African journal of medicine and medical sciences, vol. 29, no. 3-4, pp. 233–237, 2000. View at Google Scholar · View at Scopus
  13. R. Newton, J. Ziegler, V. Beral et al., “A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda,” International Journal of Cancer, vol. 92, no. 5, pp. 622–627, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Sitas, R. Pacella-Norman, H. Carrara et al., “The spectrum of HIV-1 related cancers in South Africa,” International Journal of Cancer, vol. 88, no. 3, pp. 489–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Stein, M. I. Urban, D. O'Connell et al., “The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995–2004,” International Journal of Cancer, vol. 122, no. 10, pp. 2260–2265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. D. M. Parkin, H. Garcia-Giannoli, M. Raphael et al., “Non-Hodgkin lymphoma in Uganda: a case-control study,” AIDS, vol. 14, no. 18, pp. 2929–2936, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. K. N. Naresh, M. Raphael, L. Ayers et al., “Lymphomas in sub-Saharan Africa—what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?” British Journal of Haematology, vol. 154, no. 6, pp. 696–703, 2011. View at Publisher · View at Google Scholar
  18. J. Orem, M. W. Otieno, and S. C. Remick, “AIDS-associated cancer in developing nations,” Current Opinion in Oncology, vol. 16, no. 5, pp. 468–476, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. H. R. Wabinga, D. M. Parkin, F. Wabwire-Mangen, and S. Nambooze, “Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997,” British Journal of Cancer, vol. 82, no. 9, pp. 1585–1592, 2000. View at Google Scholar · View at Scopus
  20. D. M. Parkin, S. Nambooze, F. Wabwire-Mangen, and H. R. Wabinga, “Changing cancer incidence in Kampala, Uganda, 1991–2006,” International Journal of Cancer, vol. 126, no. 5, pp. 1187–1195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. J. Achenbach, S. R. Cole, M. M. Kitahata et al., “Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy,” AIDS, vol. 25, no. 5, pp. 691–700, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. H. Bateganya, J. Stanaway, P. E. Brentlinger et al., “Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 4, pp. 312–319, 2011. View at Publisher · View at Google Scholar
  23. J. F. Lester, S. D. Dojcinov, R. L. Attanoos et al., “The clinical impact of expert pathological review on lymphoma management: a regional experience,” British Journal of Haematology, vol. 123, no. 3, pp. 463–468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. N. A. Othieno-Abinya, H. O. Abwao, J. M. D. Maina et al., “Non-Hodgkin's lymphomas at Kenyatta the National Hospital Nairobi in the 1990's,” East African Medical Journal, vol. 81, no. 9, pp. 450–458, 2004. View at Google Scholar · View at Scopus
  25. E. Parkins et al., “UK-based real-time lymphoproliferative disorder diagnostic service to improve the management of patients in Ghana,” Journal of Hematopathology, vol. 2, no. 3, pp. 143–149, 2009. View at Google Scholar
  26. W. O. Mwanda, J. Orem, P. Fu et al., “Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa,” Journal of Clinical Oncology, vol. 27, no. 21, pp. 3480–3488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. K. N. Naresh, H. A. H. Ibrahim, S. Lazzi et al., “Diagnosis of Burkitt lymphoma using an algorithmic approach - applicable in both resource-poor and resource-rich countries,” British Journal of Haematology, vol. 154, no. 6, pp. 770–776, 2011. View at Publisher · View at Google Scholar
  28. L. K. Tumwine, C. Agostinelli, C. Campidelli et al., “Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda,” BMC Clinical Pathology, vol. 9, article 11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. J. Jones, N. A. G. Goad, K. R. Muir, S. E. Parkes, C. D. Evans, and J. R. Mann, “Immunophenotypic analysis of childhood Burkitt's lymphoma in the West Midlands 1957–1986,” Journal of Clinical Pathology, vol. 48, no. 1, pp. 22–25, 1995. View at Google Scholar · View at Scopus
  30. A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1812–1821, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Ziegler, J. A. Beckstead, and P. A. Volberding, “Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome,” The New England Journal of Medicine, vol. 311, no. 9, pp. 565–570, 1984. View at Google Scholar · View at Scopus
  32. P. S. Gill, A. M. Levine, M. Krailo et al., “AIDS-related malignant lymphoma: results of prospective treatment trials,” Journal of Clinical Oncology, vol. 5, no. 9, pp. 1322–1328, 1987. View at Google Scholar · View at Scopus
  33. L. D. Kaplan, D. I. Abrams, E. Feigal et al., “AIDS-associated non-Hodgkin's lymphoma in San Francisco,” Journal of the American Medical Association, vol. 261, no. 5, pp. 719–724, 1989. View at Google Scholar · View at Scopus
  34. L. D. Kaplan, D. J. Straus, M. A. Testa et al., “Low-dose compared with standard-dose m-BACOD chemotherapy for non- Hodgkin's lymphoma associated with human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 336, no. 23, pp. 1641–1648, 1997. View at Publisher · View at Google Scholar
  35. N. Mounier, M. Spina, J. Gabarre et al., “AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy,” Blood, vol. 107, no. 10, pp. 3832–3840, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Moh, C. Danel, S. Sorho et al., “Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire,” Antiviral Therapy, vol. 10, no. 5, pp. 615–624, 2005. View at Google Scholar · View at Scopus
  37. M. W. Otieno, S. C. Remick, and C. Whalen, “Adult burkitt's lymphoma in patients with and without human immunodeficiency virus infection in Kenya,” International Journal of Cancer, vol. 92, no. 5, pp. 687–691, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. L. D. Kaplan, J. Y. Lee, R. F. Ambinder et al., “Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010,” Blood, vol. 106, no. 5, pp. 1538–1543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Dunleavy, R. F. Little, S. Pittaluga et al., “The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma,” Blood, vol. 115, no. 15, pp. 3017–3024, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. J. A. Sparano, J. Y. Lee, L. D. Kaplan et al., “Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma,” Blood, vol. 115, no. 15, pp. 3008–3016, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. C. Remick, N. Sedransk, R. Haase et al., “Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies,” Drugs, vol. 58, no. 3, supplement, pp. 99–107, 1999. View at Google Scholar · View at Scopus
  42. Centers for Disease Control and Prevention (CDC), “Progress toward strengthening national blood transfusion services—14 countries, 2008–2010.,” MMWR: Morbidity and Mortality Weekly Report, vol. 60, no. 46, pp. 1577–1582, 2011. View at Google Scholar
  43. J. M. Sloan and K. Ballen, “SCT in Jehovah's Witnesses: the bloodless transplant,” Bone Marrow Transplantation, vol. 41, no. 10, pp. 837–844, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. S. Gill, C. Loureiro, M. Bernstein-Singer, M. U. Rarick, F. Sattler, and A. M. Levine, “Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS),” Annals of Internal Medicine, vol. 110, no. 11, pp. 937–940, 1989. View at Google Scholar · View at Scopus
  45. Y. Kobashi and T. Matsushima, “Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy,” Internal Medicine, vol. 41, no. 12, pp. 1103–1110, 2002. View at Google Scholar · View at Scopus
  46. A. L. Cheng, “Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma,” Blood, vol. 87, no. 3, p. 1202, 1996. View at Google Scholar · View at Scopus
  47. X. Q. Chen, J. W. Peng, G. N. Lin, M. Li, and Z. J. Xia, “The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy,” Medical Oncology. In press. View at Publisher · View at Google Scholar
  48. E. Seremba, P. Ocama, C. K. Opio et al., “Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda,” Journal of Medical Virology, vol. 82, no. 8, pp. 1334–1340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. F. M. Knaul, Frenk, Julio, and Shulman, Lawrence for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries, Harvard Global Equity Initiative, Boston, Mass, USA, October 2011.
  50. D. E. Bloom, E. T. Cafiero, E. Jané-Llopis et al., The Global Economic Burden of Noncommunicable Diseases, World Economic Forum, Geneva, Switzerland, 2011.
  51. L. A. Jones, J. A. Chilton, R. A. Hajek, N. K. Iammarino, and L. Laufman, “Between and within: international perspectives on cancer and health disparities,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2204–2208, 2006. View at Publisher · View at Google Scholar · View at Scopus